Press ReleasesIndustrialsMedical Device Software Global Market Access Training Course | Explore Regulatory Pathways and Reimbursement Strategies Across Jurisdictions (ONLINE EVENT: September 8-9, 2025)

June 30, 2025

Medical Device Software Global Market Access Training Course | Explore Regulatory Pathways and Reimbursement Strategies Across Jurisdictions (ONLINE EVENT: September 8-9, 2025)

Master market access for medical device software with our expert-led course. Navigate international regulations, understand reimbursement pathways, and enhance commercial success globally. Gain insights with real-life examples and earn CPD certification. Join now to ensure market entry success!

Master market access for medical device software with our expert-led course. Navigate international regulations, understand reimbursement pathways, and enhance commercial success globally. Gain insights with real-life examples and earn CPD certification. Join now to ensure market entry success!

Source: https://www.globenewswire.com/news-release/2025/06/30/3107315/28124/en/Medical-Device-Software-Global-Market-Access-Training-Course-Explore-Regulatory-Pathways-and-Reimbursement-Strategies-Across-Jurisdictions-ONLINE-EVENT-September-8-9-2025.html

Millionero Issues Urgent Warning on Rising Phishing Scams: How Users Can Stay Protected in 2025

Scalefusion Partners with Hermitage Solutions to Expand Endpoint Security & UEM Reach Across Europe

globenewswire

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

Commodities & Resources PTE Ltd. Announces Acquisition of Shares of Belmont Resources Inc. Pursuant to Private Placement

APPLOVIN ALERT: Bragar Eagel & Squire, P.C. is Investigating AppLovin Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Medical Device Software Global Market Access Training Course | Explore Regulatory Pathways and Reimbursement Strategies Across Jurisdictions (ONLINE EVENT: September 8-9, 2025)

Commodities & Resources PTE Ltd. Announces Acquisition of Shares of Belmont Resources Inc. Pursuant to Private Placement

APPLOVIN ALERT: Bragar Eagel & Squire, P.C. is Investigating AppLovin Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

First AML expands Tranche 2 leadership in Australia following major client wins across law and real estate

ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST

ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST

Recent News

First AML expands Tranche 2 leadership in Australia following major client wins across law and real estate

ASIA’S 50 BEST BARS 2025 REVEALS THE ESTABLISHMENTS RANKED ON THE EXTENDED 51-100 LIST

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Explore

Press Releases

News & Opinion

Living

Others

Follow us

Techcon Launches New Side-By-Side Dispensing Cartridge Line

Regarding the New Wording of Draft Resolutions for the General Meeting of Shareholders Convened...

Le Fonds humanitaire des Métallos soutient les efforts d’aide aux victimes des feux de...